Ionotropic glutamate receptors antagonists are now widely considered as potential medications for a variety of disorders, such as seizures, neurodegenerative diseases, stroke, and opiate tolerance and dependence. There is a growing body of evidence suggesting that the safest drugs are to be found amongst antagonists acting at glycine and polyamine sites of NMDA-receptor complex, low-affinity channel blockers, subtype-selective competitive NMDA-receptor antagonists, as well as non-NMDA glutamate receptors antagonists. These antagonists exhibit little or no abuse liability and are less likely to induce phencyclidine-like attention deficits and disruption of sensomotor gating. Meanwhile, these drugs retain most of the potentially useful properties, including anxiolytic and antidepressant effects.
Download full-text PDF |
Source |
---|
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!